FINWIRES · TerminalLIVE
FINWIRES

MAIA Biotechnology Says 29 Patients Dosed in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer Treatment

By

MAIA Biotechnology (MAIA) said Thursday that 29 patients have been dosed in its phase 3 trial evaluating its novel telomere-targeting therapy as a third-line treatment for advanced non-small cell lung cancer.

Vlad Vitoc, MAIA chief executive, said the company is expecting to dose up to 100 patients by year-end and to have sufficient survival data to conduct an interim analysis in 2027.

The trial involves 34 activated trial sites in six countries, the company said.

MAIA shares were more than 3% higher in Thursday trading.

Price: $1.48, Change: $+0.06, Percent Change: +4.00%

Related Articles

Wire

BHP Signs Potash Transport Deals With Canada's National Rail Carriers

BHP Group's (BHP) BHP Canada subsidiary said Thursday it signed transportation agreements with Canadian National Railway (CNI) and Canadian Pacific Kansas City (CP) that will help move potash from its Jansen project in Saskatchewan to Westshore Terminals in Vancouver for export.Both Canadian National and Canadian Pacific will operate unit trains between Jansen and Westshore Terminals under roughly four-year contracts, BHP said."The Jansen Potash Mine project represents a generational investment in Saskatchewan and a significant opportunity for Canada's export economy," CN Chief Commercial Officer Janet Drysdale said."We are pleased to enter into this agreement with BHP as they expand into the potash market," said Canadian Pacific President and CEO Keith Creel. "We look forward to providing our industry-leading service to BHP helping to drive innovation and reliability across the potash supply chain."Price: $89.55, Change: $-1.30, Percent Change: -1.43%

$BHP$CNI$CP
Wire

BofA Securities Raises Broadcom Price Target to $530 From $450 as 'AI Growth on Track', Maintains Buy Rating

Broadcom (AVGO) has an average rating of Buy and mean price target of $505.74, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $406.19, Change: $-73.04, Percent Change: -15.24%

$AVGO
Wire

Update: Wedbush Lifts Price Target on CrowdStrike to $720 From $700 as 'Cyber-AI Strategy Continues to Play Out', Maintains Outperform Rating

(Updated to include Wedbush commentary)Wedbush raised its price target on CrowdStrike (CRWD) to $720 from $700 following the company's reported Q1 results with slight beats across the board, as well as the full-year guidance raise.The cybersecurity technology company continues to see an expansive pipeline for its cyber-AI product portfolio that remains a significant driver of its bookings pipeline, analysts led by Dan Ives wrote in a Thursday note.CrowdStrike's position as the gold standard of cybersecurity remains intact with its innovative, best-in-class Falcon platform becoming increasingly important in the new modern AI threat landscape, the analysts mentioned.CrowdStrike has an average rating of overweight and mean price target of $646.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $684.28, Change: $-63.34, Percent Change: -8.47%

$CRWD